CIS (compliance implementation services) has appointed David Greeley as VP of GMP Compliance.
Greeley comes to the Philadelphia-based pharmaceutical compliance consulting firm with a solid track record in areas such as strategic planning, business development, and P&L management.
In his new role, Greeley will oversee the manufacturing practice group, helping clients meet cGMP (current good manufacturing practice) in a number of fields, including document control systems, inspection readiness, internal system audits, development of Key Performance Indicators, and training.
Of his new position he said: “I am elated to bring my industry expertise to CIS in leading the Manufacturing Practice Group and expand the services we currently offer.”
Christopher O’Connell has joined Marken as the new CFO, and Frank Wright has joined as the interim president of the clinical trials distribution business unit.
Prior to working for Marken, O’Connell worked for Thermo Fisher Scientific as VP of finance in the Customer Channels Group; a multi-national laboratory distribution and services group.
"Chris' business insight, combined with his extensive financial leadership, acquisition integration expertise and pharmaceutical services and supplies familiarity at Thermo Fisher, make him an excellent addition to our executive leadership team,” said Wes Wheeler, CEO of Marken.
Whereas Wright will continue to build Marken’s distribution capability for drug product and kits from clients to depots and investigator sites around the world.
Wheeler added: “I look forward to working closely with Frank as we continue to build our clinical trials distribution business.”
Verastem have named Jonathan Pachter as their new VP and head of research.
Pachter comes to the biopharmaceutical company – who focuses on drug discovery and development for oncology – from his position as head of cancer biology at OSI Pharmaceuticals; acquired by Astella.
Robert Weinberg, Verastem co-founder and co-chair of the Scientific Advisory Board, said: “Jon has been instrumental in progressing the science of EMT and cancer stem cells into the clinic.
“His ability to drive research will help Verastem deliver on the promise of new treatments for patients with incurable cancer.”
MicroConstants has hired Lilin Wang as the new manager of their immunology department.
The company says his expertise will enable it to provide additional contract research services to pharmaceutical and biotech companies developing large molecule drugs and other biologics.
In addition to leading the expansion of MicroConstants’ immunology department, Lilin will serve as a principal investigator and direct the development and validation of ELISA immunoassays, enzymatic activity assays, and immunogenicity testing for pharmaceuticals, biomarkers, and antibodies.
David Beyerlein, vice president of global operations at MicroConstants, said: “Our immunology department was established in 2007 to provide immunoassay and biomarker analysis services to clients developing proteins and peptides.
“Lilin’s experience will allow us to expand those services to also include cell-based and molecular assay development which can provide insight into drug metabolism and drug target interactions in vivo.”
Former PRTM principle John Ebeid is set to take on the role of VP at Delta Outsourcing, a division of Delta Pharma and Randstad.
Ebeid will take on the strategic direction for Delta's outsourcing business, which provides professional consulting services including medical writing, pharmacovigilance, clinical and medical management/monitoring, statistics/data management, project management, and regulatory strategy/QA services.
“John is a recognized leader in the industry and we are very excited to have him join our team," said Greg Coir, president of Delta Outsourcing. "His success developing global R&D operating models and sourcing strategies for major biopharmaceutical companies, both working the front lines and as a consultant, will be vital to the outsourcing projects he will be leading for our clients."
Southern Research Institute announced that Mark Suto has been named VP of their drug discovery division.
Suto and his team will focus on basic research and target identification and lead discovery and optimization of new therapies for cancer, infectious diseases and neurological diseases and disorders.
Prior to his appointment at SRI, Suto was VP, chemical and pharmaceutical sciences at Icagen.
“Mark Suto has demonstrated outstanding scientific and management skills in his career, and adds tremendous strength to our Drug Discovery program," said Jack Secrist, President and CEO.
Norman Baylor has become CEO at Biologics Consulting Group, leaving behind a 20-year career with the FDA.
Baylor, most recently director of the office of vaccines research and review board (OVRR), replaces Jim Kenimer.
Kenimer, who will remain as chairman of the BCG Board said: “We are delighted to welcome Norman to BCG's management team.
“The BCG team looks forward to working with Norman in support of our clients' goals to advance the future of vaccines, biologics, drugs, and medical devices.”